Shattuck Labs, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

– aberrant trim7 expression identified as a key driver of immune checkpoint blockade (icb) acquired resistance; inhibition of trim7 with small molecule inhibitors may prevent or reverse acquired resistance to pd-1/l1 blockade –

Austin, tx & durham, nc, april 01, 2024 (globe newswire) -- shattuck labs, inc. (shattuck) (nasdaq: sttk), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 23rd annual needham virtual healthcare conference being held virtually from april 8-11, 2024.

Austin, tx and durham, nc, march 04, 2024 (globe newswire) -- shattuck labs, inc. (shattuck) (nasdaq: sttk), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of clay siegall, ph.d., and kate sasser, ph.d., to its board of directors, effective march 1, 2024. both dr. siegall and dr. sasser are highly successful executives and scientific pioneers who bring valuable industry experience to shattuck.

- announced positive topline data from the ongoing phase 1a/b clinical trial of sl-172154 in combination with azacitidine (aza) in frontline higher-risk myelodysplastic syndromes (hr-mds) and frontline tp53 mutant (tp53m) acute myeloid leukemia (aml) patients; initial data build on the dose-escalation data featured in a poster presentation at the american society of hematology (ash) annual meeting –

Austin, tx and durham, nc, feb. 26, 2024 (globe newswire) -- shattuck labs, inc. (shattuck) (nasdaq: sttk), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in march 2024.

Positive results were released from the phase 1A/B study, using SL-172154 in combination with azacitidine for the treatment of patients with front-line higher-risk myelodysplastic syndrome and TP53 mutant acute myeloid leukemia. Additional results from the phase 1A/B study, using SL-172154 in combination with azacitidine for the treatment of patients with front-line HR-MDS and TP53 mutant AML, expected by mid-2024. The global myelodysplastic syndrome treatment market will reach $5.61 billion by 2032.

Shattuck Labs (NASDAQ: STTK ) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial. These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m Acute Myeloid Leukemia (AML) patients.

AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call on initial data from its ongoing frontline expansion cohorts in HR-MDS and TP53m AML and review data from the poster presentation featured at the 65th ASH Annual Meeting on Wednesday, December 13, 2023 at 8:00 a.m. ET.

Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Conor Richardson – Vice President-Investor Relations Taylor Schreiber – Scientific Co-Founder and Chief Executive Officer Lini Pandite – Chief Medical Officer Andrew Neill – Chief Financial Officer Conference Call Participants Jonathan Miller – Evercore ISI Joe Pantginis – H.C. Wainwright Marc Frahm – TD Cowen Yigal Nochomovitz – Citi Gil Blum – Needham & Company Operator Good morning and welcome to the Shattuck Labs Third Quarter 2023 Earnings Conference Call.

AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023.

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose –

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.58 per share a year ago.

Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.

Shattuck Labs, Inc. (NASDAQ:STTK ) Q4 2022 Earnings Conference Call February 23, 2023 4:45 PM ET Company Participants Conor Richardson - Vice President, Investor Relations Taylor Schreiber - Chief Executive Officer and Scientific Co-Founder Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore ISI Marc Frahm - Cowen Yigal Nochomovitz - Citi Zhiqiang Shu - Berenberg Operator Good afternoon, ladies and gentlemen. Welcome to the Shattuck Labs Fourth Quarter and Full Year 2022 Earnings Conference Call.